
Prostate cancer is the most common malignancy in American men following skin cancer, with approximately one in eight men being diagnosed during their lifetime. Over the past several decades, the treatment of prostate cancer has evolved rapidly, and so too has been screened. Since the mid-2010s, magnetic resonance imaging (MRI)–guided biopsies or ‘targeted biopsies’ have been a rapidly growing topic of clinical research within urologic oncology. This publication aims to provide a review of biparametric MRI (bpMRI) utilization for diagnosing prostate cancer and comparison to multiparametric MRI (mpMRI). When compared with the diagnostic accuracy of mpMRI, bpMRI identifies prostate cancer at comparable rates. In addition, when omitting dynamic contrast-enhanced (DCE) protocol to the MRI, patients incur reduced costs and shorter imaging time while providers can offer more tests to their patient population.
Like
Save
Share